- Home
- ADUS vs KNSA Comparison
ADUS vs KNSA Comparison
Compare ADUS & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADUS
- KNSA
- Stock Information
- Founded
- ADUS 1979
- KNSA 2015
- Country
- ADUS United States
- KNSA United Kingdom
- Employees
- ADUS N/A
- KNSA N/A
- Industry
- ADUS Medical/Nursing Services
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- ADUS Health Care
- KNSA Health Care
- Exchange
- ADUS Nasdaq
- KNSA Nasdaq
- Market Cap
- ADUS 1.8B
- KNSA 1.9B
- IPO Year
- ADUS 2009
- KNSA 2018
- Fundamental
- Price
- ADUS $110.23
- KNSA $27.39
- Analyst Decision
- ADUS Buy
- KNSA Strong Buy
- Analyst Count
- ADUS 10
- KNSA 5
- Target Price
- ADUS $143.50
- KNSA $38.80
- AVG Volume (30 Days)
- ADUS 179.2K
- KNSA 474.9K
- Earning Date
- ADUS 05-05-2025
- KNSA 07-22-2025
- Dividend Yield
- ADUS N/A
- KNSA N/A
- EPS Growth
- ADUS 9.84
- KNSA N/A
- EPS
- ADUS 4.42
- KNSA N/A
- Revenue
- ADUS $1,211,561,000.00
- KNSA $481,166,000.00
- Revenue This Year
- ADUS $23.33
- KNSA $37.21
- Revenue Next Year
- ADUS $5.69
- KNSA $5.32
- P/E Ratio
- ADUS $25.12
- KNSA N/A
- Revenue Growth
- ADUS 11.38
- KNSA 59.45
- 52 Week Low
- ADUS $88.96
- KNSA $17.38
- 52 Week High
- ADUS $136.72
- KNSA $28.56
- Technical
- Relative Strength Index (RSI)
- ADUS 55.53
- KNSA 63.27
- Support Level
- ADUS $108.46
- KNSA $26.58
- Resistance Level
- ADUS $115.94
- KNSA $27.90
- Average True Range (ATR)
- ADUS 2.81
- KNSA 0.99
- MACD
- ADUS -0.33
- KNSA -0.06
- Stochastic Oscillator
- ADUS 43.47
- KNSA 85.45
About ADUS Addus HomeCare Corporation
Addus HomeCare Corp is engaged in the provision of in-home personal care services. It operates through the segments such as Personal care segment, which is a key revenue driver, provides non-medical assistance with activities of daily living, primarily to persons who are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. The Hospice segment provides physical, emotional and spiritual care for people who are terminally ill and their families. Its Home health segment provides services that are primarily medical in nature to those individuals who may require assistance during an illness or after surgery.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.